Key result
Newer anti-platelet and anti-thrombotic agents, such as prasugrel, ticagrelor, bivalirudin, and fondaparinux, improve clinical outcomes by more effectively balancing anti-ischemic benefits and bleeding risks in acute coronary syndromes.
Why the study?
Do novel anti-platelet and anti-thrombotic therapies improve ischemic outcomes or reduce bleeding compared to standard therapies in patients with acute coronary syndromes?
Do novel anti-platelet and anti-thrombotic therapies improve ischemic outcomes or reduce bleeding compared to standard therapies in patients with acute coronary syndromes?
Emerging anti-platelet and anti-thrombotic agents offer more consistent and targeted inhibition of thrombosis, providing options to tailor therapy based on individual ischemic and bleeding risks in ACS.
In the majority of cases acute coronary syndromes (ACS) are caused by activation and aggregation of platelets and subsequent thrombus formation leading to a decrease in coronary artery blood flow. Recent focus on the treatment of ACS has centered on reducing the response of platelets to vascular injury as well as inhibiting fibrin deposition. Novel therapies include more effective P2Y12 receptor blockers thereby reducing inter-individual variability, targeting the platelet thrombin receptor (protease activated receptor 1) as well as directly inhibiting factor Xa or thrombin activity. In this review we discuss the clinical data evaluating the effectiveness of these various new ACS treatment options.
No takes yet. Share an insight, caveat, or question.
Lilly et al. (2011) conducted a review in Acute coronary syndromes. Emerging anti-platelet and anti-thrombotic therapies was evaluated. Newer anti-platelet and anti-thrombotic agents, such as prasugrel, ticagrelor, bivalirudin, and fondaparinux, improve clinical outcomes by more effectively balancing anti-ischemic benefits and bleeding risks in acute coronary syndromes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: